Autolus Therapeutics (AUTL) Enterprise Value (2017 - 2025)
Autolus Therapeutics (AUTL) has disclosed Enterprise Value for 9 consecutive years, with -$367.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 44.21% year-over-year to -$367.4 million, compared with a TTM value of -$367.4 million through Sep 2025, up 44.21%, and an annual FY2024 reading of -$228.8 million, up 4.49% over the prior year.
- Enterprise Value was -$367.4 million for Q3 2025 at Autolus Therapeutics, down from -$125.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$97.3 million in Q1 2025 and bottomed at -$759.5 million in Q1 2024.
- Average Enterprise Value over 5 years is -$347.8 million, with a median of -$307.8 million recorded in 2023.
- The sharpest move saw Enterprise Value plummeted 39426.21% in 2021, then skyrocketed 87.2% in 2025.
- Year by year, Enterprise Value stood at -$310.7 million in 2021, then dropped by 23.2% to -$382.8 million in 2022, then surged by 37.41% to -$239.6 million in 2023, then increased by 4.49% to -$228.8 million in 2024, then crashed by 60.57% to -$367.4 million in 2025.
- Business Quant data shows Enterprise Value for AUTL at -$367.4 million in Q3 2025, -$125.3 million in Q2 2025, and -$97.3 million in Q1 2025.